Related Experiment Video
Updated: Oct 25, 2025
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.8K
Oxaliplatin-induced hepatic sinusoidal obstruction syndrome
Chen Zhu1, Xiuhua Ren1, Dong Liu1
1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Toxicology
|August 5, 2021
Summary
Oxaliplatin chemotherapy can cause hepatic sinusoidal obstruction syndrome (HSOS) in colorectal cancer patients. This review covers HSOS epidemiology, mechanisms, and potential prevention strategies.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Oxaliplatin (OXA) is a key chemotherapy agent for metastatic colorectal cancer (CRC).
- Oxaliplatin-induced hepatic sinusoidal obstruction syndrome (HSOS) is a significant clinical concern.
- HSOS presents with splenomegaly, thrombocytopenia, abnormal liver function, and portal hypertension.
Purpose of the Study:
- To review the epidemiology and pathological characteristics of OXA-induced HSOS.
- To identify clinical predictive indicators for HSOS.
- To explore the mechanisms and potential prevention/treatment strategies for OXA-related HSOS.
Main Methods:
- Literature review of studies on Oxaliplatin and HSOS.
- Synthesis of information on HSOS pathogenesis, clinical features, and management.
- Analysis of proposed mechanisms including oxidative stress, inflammation, fibrosis, and platelet aggregation.
Main Results:
- HSOS is a serious adverse event associated with Oxaliplatin treatment in CRC.
- Pathogenesis involves complex mechanisms like oxidative stress and liver fibrosis.
- Currently, no specific treatments exist for OXA-induced HSOS.
Conclusions:
- Oxaliplatin-induced HSOS requires further research for effective prevention and treatment.
- Understanding the underlying mechanisms is crucial for developing targeted therapies.
- Clinical monitoring and early identification of risk factors are important for managing HSOS in CRC patients.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
398
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
398
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
309
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
309
01:21Drugs for Treatment of Constipation-Predominant IBS
408
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
408
01:21Hepatic Portal System
3.1K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
3.1K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
375
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
375
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
37
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
37